Topical glaucoma medications: Clinical implications for the ocular surface

Fredrik Fineide*, Neil Lagali, Muhammed Yasin Adil, Reiko Arita, Miriam Kolko, Jelle Vehof, Tor P. Utheim

*Corresponding author for this work

    Research output: Contribution to journalReview articlepeer-review

    19 Citations (Scopus)
    94 Downloads (Pure)

    Abstract

    Glaucoma is a leading cause of irreversible blindness. The use of topical eye drops to reduce intraocular pressure remains the mainstay treatment. These eye drops frequently contain preservatives designed to ensure sterility of the compound. A growing number of clinical and experimental studies report the detrimental effects of not only these preservatives but also the active pharmaceutical compounds on the ocular surface, with resultant tear film instability and dry eye disease. Herein, we critically appraise the published literature exploring the effects of preservatives and pharmaceutical compounds on the ocular surface.

    Original languageEnglish
    Pages (from-to)19-49
    Number of pages31
    JournalOcular Surface
    Volume26
    DOIs
    Publication statusPublished - Oct-2022

    Keywords

    • Dry eye disease
    • Eyedrops
    • Glaucoma
    • Meibomian gland dysfunction
    • Topical medications

    Fingerprint

    Dive into the research topics of 'Topical glaucoma medications: Clinical implications for the ocular surface'. Together they form a unique fingerprint.

    Cite this